ArticleBMC complementary medicine and therapies2025
Anticancer and cancer preventive activities of shogaol and curcumin from Zingiberaceae family plants in KG-1a leukemic stem cells.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Therapeutic Potential of Ginger Rhizomes (Zingiber officinale) on Leukemia.Biotechnology and applied biochemistry · 2026Review
- 6-Shogaol fromInternational journal of molecular sciences · 2026Article
- Modulation of breast cancer progression in high-altitude hypoxia by Tongqiaohuoxue Decoction via HIF-1α/VEGF signaling.Discover oncology · 2026Article
- Galangin and 1'-Acetoxychavicol Acetate from Galangal (Biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLeukemic stem cells (LSCs) present a significant challenge in the treatment of leukemia in patients because they exhibit a drug-resistant phenotype, making them difficult to eliminate. Searching for a new anticancer drug is crucial for improving leukemia treatment. Plants from the Zingiberaceae family are frequently used in traditional medicines due to their safety and accessibility. This study explores the anticancer activity, cancer preventive properties, and apoptosis inducing mechanisms of active compounds derived from these plants.
methodsTen crude ethanolic extracts from each plant of the Zingiberaceae family were obtained using maceration techniques. The cytotoxicity of all extracts anticancer was assessed in comparison to anticancer drugs (cyclophosphamide, cytarabine, doxorubicin, and idarubicin) using MTT assay on cancer cell lines (KG-1a, K562, A549, MCF-7, and HeLa) and peripheral blood mononuclear cells (PBMCs). Cancer prevention properties of the effective extracts and their active compounds were evaluated by measuring the levels of tumor necrosis factor-alpha (TNF-α), interleukin-2 (IL-2), and nitric oxide (NO) using commercial kits. Cell cycle and cell death analyses were conducted using flow cytometry. Moreover, the effects of effective extracts and their active compounds on WT1 and CD34 expressions, as well as the apoptosis mechanism induced by the active compounds in KG-1a cells, were determined by Western blotting.
resultsThe cytotoxicity tests revealed that crude ethanolic extracts from Curcuma longa, C. zedoaria, and Zingiber officinale exhibited effective cytotoxicity against cancer cell lines while demonstrating lower impact on PBMCs. The active compounds of C. longa and C. zedoaria are curcuminoids, while those in Z. officinale are shogaol and gingerol. Notably, the IC
conclusionThese findings highlight shogaol and curcumin as promising compounds for leukemia treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.